Press Releases

Date Title and Summary    
Toggle Summary Rexahn Initiates Patient Dosing in Phase I Clinical Trial at Georgetown University Lombardi Cancer Center
Rockville, MD – September 28, 2004 – Rexahn Corporation, a privately held biopharmaceutical company, announced today its RX-0201 clinical trial program for the treatment of advanced or metastasized cancers is underway at the Georgetown University Hospital Lombardi Cancer Center in Washington, DC.
View HTML Print
Toggle Summary Rexahn Initiates First Clinical Trial RX-0201 Phase I Clinical Trial for Patients with Malignancy
Rockville, MD. – June 1, 2004 – Rexahn Corporation, a privately held emerging biopharmaceutical company, announced today it will initiate its first clinical trial program for the treatment of patients with advanced or metastasized cancers in June 2004.
View HTML Print
Toggle Summary Rexahn Submits First Clinical Trial Package to FDA RX-0201 Phase I Clinical Trial for Patients with Malignancy
Rockville, MD. – April 30, 2004 – Rexahn, Inc., a privately held emerging biopharmaceutical company announced today it has submitted its RX-0201 clinical trial package to the FDA for the treatment of patients with advanced or metastasized cancers. The Phase I clinical study will be conducted at
View HTML Print
Toggle Summary Rexahn Files Patent Application for Anti-Cancer Drug Nucleosides
Rockville, MD, April 1, 2004 – Rexahn, an emerging, privately-held biopharmaceutical company focusing on the development of first-in-class signal inhibitor therapeutics, announced today that it has submitted a provisional patent application for its anti-cancer drug candidate, nucleosides.
View HTML Print
Toggle Summary Rexahn Files Patent Application for Quinazoline-Based Anti-Cancer Drug Candidate
Rockville, MD, February 19, 2004 – Rexahn, an emerging, privately-held biopharmaceutical company focusing on the development of first-in-class signal inhibitor therapeutics, announced today that it has submitted a provisional patent application for its Quinazoline-based anti-cancer drug candidates.
View HTML Print
Toggle Summary Rexahn Receives $100,000 Technology Growth Program Grant from Montgomery County
Rockville, MD, January 9, 2004 – Rexahn Corporation announced today that that it has received the prestigious $100,000 as a Technology Growth Program (TGP) Grant from Department of Economic development of Montgomery County, Maryland. TGP was created in 1999 to stimulate and facilitate growth and
View HTML Print
Toggle Summary Rexahn Completes $2,000,000 Private Placement from KT&G Corporation
Rockville, MD, August 7, 2003 – Rexahn Corp. announced today that that it has raised a $2,000,000 through the sale in a private placement of 500,000 shares of common stock to KT&G Corporation. Furthermore, through the MOU on June 24, 2003, KT&G will consider supporting the research and development
View HTML Print
Toggle Summary Rexahn Announces Crada Agreement with The National Cancer Institute
Rockville, MD, May 6, 2003 – Rexahn Corp. announced today that it has signed a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health. The agreement provides for NCI and Rexahn to investigate the effect of a family of
View HTML Print
Toggle Summary Rexahn Announces Joint Research Agreement with The KRICT
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has entered into a joint research agreement with the Korea Research Institute of Chemical Technology (KRICT), a quasi-government research institute in Korea. The purpose of this collaboration is to accelerate the discovery of
View HTML Print
Toggle Summary Rexahn Announces Filing of a Patent Application for a Novel Anti-Cancer
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has submitted a patent application for its recently discovered anti-cancer drug, RX-0047. The new drug candidate inhibits expression of HIF-1, a human protein that leads to rapid cancer growth.
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy